Published in Cardiovasc Res on February 15, 2008
Systems medicine and integrated care to combat chronic noncommunicable diseases. Genome Med (2011) 1.78
Stem cell therapy for vascular regeneration: adult, embryonic, and induced pluripotent stem cells. Circulation (2010) 1.67
Angiogenesis in the infarcted myocardium. Antioxid Redox Signal (2012) 1.15
Platelet function in patients with diabetes mellitus: from a theoretical to a practical perspective. Int J Endocrinol (2011) 1.12
Factors contributing to increased platelet reactivity in people with diabetes. Diabetes Care (2009) 0.99
Reactive oxygen species, reactive nitrogen species and antioxidants in etiopathogenesis of diabetes mellitus type-2. Indian J Clin Biochem (2009) 0.99
Mitochondrial function in vascular endothelial cell in diabetes. J Smooth Muscle Res (2012) 0.96
Absence of mannose-binding lectin prevents hyperglycemic cardiovascular complications. Am J Pathol (2011) 0.96
Evaluation of the use of an induced puripotent stem cell sheet for the construction of tissue-engineered vascular grafts. J Thorac Cardiovasc Surg (2012) 0.96
Effects of ACE inhibition on circulating endothelial progenitor cells, vascular damage, and oxidative stress in hypertensive patients. Eur J Clin Pharmacol (2011) 0.93
The role of vitamin D deficiency and vitamin d receptor genotypes on the degree of collateralization in patients with suspected coronary artery disease. Biomed Res Int (2014) 0.84
Nitric oxide: perspectives and emerging studies of a well known cytotoxin. Int J Mol Sci (2010) 0.84
Diabetes, Endothelial Dysfunction, and Vascular Repair: What Should a Diabetologist Keep His Eye on? Int J Endocrinol (2015) 0.83
Autologous Stem Cell Therapy: How Aging and Chronic Diseases Affect Stem and Progenitor Cells. Biores Open Access (2015) 0.81
MicroRNAs in vascular tissue engineering and post-ischemic neovascularization. Adv Drug Deliv Rev (2015) 0.81
Molecular mechanisms involved in the bidirectional relationship between diabetes mellitus and periodontal disease. J Indian Soc Periodontol (2013) 0.81
Far-infrared protects vascular endothelial cells from advanced glycation end products-induced injury via PLZF-mediated autophagy in diabetic mice. Sci Rep (2017) 0.77
Nitric oxide differentially affects ERK and Akt in type 1 and type 2 diabetic rats. J Surg Res (2013) 0.77
Likelihood and predictors of ST-elevation in patients hospitalized for myocardial infarction. PLoS One (2014) 0.77
The antioxidative effects of acidic-, alkalic-, and enzymatic-extractable mycelium zinc polysaccharides by Pleurotus djamor on liver and kidney of streptozocin-induced diabetic mice. BMC Complement Altern Med (2015) 0.76
Valsartan blocks thrombospondin/transforming growth factor/Smads to inhibit aortic remodeling in diabetic rats. Diagn Pathol (2015) 0.76
Different Contributions of Physical Activity on Arterial Stiffness between Diabetics and Non-Diabetics. PLoS One (2016) 0.75
Xiaokening stimulates endothelial nitric oxide release in diabetic rats. Singapore Med J (2015) 0.75
Type 1 diabetes, cardiovascular complications and sesame ( zhī má). J Tradit Complement Med (2014) 0.75
Unaltered Angiogenesis-Regulating Activities of Platelets in Mild Type 2 Diabetes Mellitus despite a Marked Platelet Hyperreactivity. PLoS One (2016) 0.75
The Promise and Challenge of Induced Pluripotent Stem Cells for Cardiovascular Applications. JACC Basic Transl Sci (2016) 0.75
Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med (2005) 27.77
Biochemistry and molecular cell biology of diabetic complications. Nature (2001) 25.43
Global burden of diabetes, 1995-2025: prevalence, numerical estimates, and projections. Diabetes Care (1998) 24.53
Regulation of endothelium-derived nitric oxide production by the protein kinase Akt. Nature (1999) 11.37
Role of oxidative stress in development of complications in diabetes. Diabetes (1991) 8.27
Endothelial progenitor cells: characterization and role in vascular biology. Circ Res (2004) 7.91
Arterial and cardiac aging: major shareholders in cardiovascular disease enterprises: Part I: aging arteries: a "set up" for vascular disease. Circulation (2003) 7.40
Matrix metalloproteinases in vascular remodeling and atherogenesis: the good, the bad, and the ugly. Circ Res (2002) 6.37
Human endothelial progenitor cells from type II diabetics exhibit impaired proliferation, adhesion, and incorporation into vascular structures. Circulation (2002) 5.82
Advanced glycation end products: sparking the development of diabetic vascular injury. Circulation (2006) 5.31
Glucose-induced reactive oxygen species cause apoptosis of podocytes and podocyte depletion at the onset of diabetic nephropathy. Diabetes (2006) 5.29
High glucose level and free fatty acid stimulate reactive oxygen species production through protein kinase C--dependent activation of NAD(P)H oxidase in cultured vascular cells. Diabetes (2000) 4.55
Endothelial progenitor cell dysfunction: a novel concept in the pathogenesis of vascular complications of type 1 diabetes. Diabetes (2004) 4.24
RAGE blockade stabilizes established atherosclerosis in diabetic apolipoprotein E-null mice. Circulation (2002) 3.93
Spatial localization of transplanted hemopoietic stem cells: inferences for the localization of stem cell niches. Blood (2001) 3.76
Arterial and cardiac aging: major shareholders in cardiovascular disease enterprises: Part III: cellular and molecular clues to heart and arterial aging. Circulation (2003) 3.62
The bone marrow vascular niche: home of HSC differentiation and mobilization. Physiology (Bethesda) (2005) 3.24
Effect of diabetes mellitus on formation of coronary collateral vessels. Circulation (1999) 3.16
Activation of NADPH oxidase by AGE links oxidant stress to altered gene expression via RAGE. Am J Physiol Endocrinol Metab (2001) 2.91
Rescue of diabetes-related impairment of angiogenesis by intramuscular gene therapy with adeno-VEGF. Am J Pathol (1999) 2.83
Amelioration of vascular dysfunctions in diabetic rats by an oral PKC beta inhibitor. Science (1996) 2.80
Improved arterial compliance by a novel advanced glycation end-product crosslink breaker. Circulation (2001) 2.74
Blood-derived angioblasts accelerate blood-flow restoration in diabetic mice. J Clin Invest (2000) 2.61
Benfotiamine blocks three major pathways of hyperglycemic damage and prevents experimental diabetic retinopathy. Nat Med (2003) 2.61
Retracted Novel role of gp91(phox)-containing NAD(P)H oxidase in vascular endothelial growth factor-induced signaling and angiogenesis. Circ Res (2002) 2.56
Human endothelial progenitor cells tolerate oxidative stress due to intrinsically high expression of manganese superoxide dismutase. Arterioscler Thromb Vasc Biol (2004) 2.39
Insulin resistance and atherosclerosis. J Clin Invest (2006) 2.27
Regulation of endothelial nitric oxide synthase by tetrahydrobiopterin in vascular disease. Arterioscler Thromb Vasc Biol (2003) 2.25
Remodeling of blood vessels: responses of diameter and wall thickness to hemodynamic and metabolic stimuli. Hypertension (2005) 2.23
Augmented BH4 by gene transfer restores nitric oxide synthase function in hyperglycemic human endothelial cells. Cardiovasc Res (2005) 2.17
Matrix metalloproteinases regulate migration, proliferation, and death of vascular smooth muscle cells by degrading matrix and non-matrix substrates. Cardiovasc Res (2005) 2.15
Endothelial nitric oxide synthase uncoupling impairs endothelial progenitor cell mobilization and function in diabetes. Diabetes (2007) 2.12
Efficacy and safety of a topical gel formulation of recombinant human platelet-derived growth factor-BB (becaplermin) in patients with chronic neuropathic diabetic ulcers. A phase III randomized placebo-controlled double-blind study. Diabetes Care (1998) 2.09
Podocyte detachment and reduced glomerular capillary endothelial fenestration in human type 1 diabetic nephropathy. Diabetes (2007) 2.08
Insulin-dependent activation of endothelial nitric oxide synthase is impaired by O-linked glycosylation modification of signaling proteins in human coronary endothelial cells. Circulation (2002) 2.02
Suppression of endothelial progenitor cells in human coronary artery disease by the endogenous nitric oxide synthase inhibitor asymmetric dimethylarginine. J Am Coll Cardiol (2005) 1.99
Vascular remodeling. Hypertension (1996) 1.99
Nitric oxide cytoskeletal-induced alterations reverse the endothelial progenitor cell migratory defect associated with diabetes. Diabetes (2006) 1.96
Leukocyte-endothelial interaction is augmented by high glucose concentrations and hyperglycemia in a NF-kB-dependent fashion. J Clin Invest (1998) 1.87
High glucose impairs early and late endothelial progenitor cells by modifying nitric oxide-related but not oxidative stress-mediated mechanisms. Diabetes (2007) 1.86
Small artery structure in hypertension. Dual processes of remodeling and growth. Hypertension (1993) 1.85
Nerve growth factor promotes angiogenesis and arteriogenesis in ischemic hindlimbs. Circulation (2002) 1.85
Vascular inflammation in hypertension and diabetes: molecular mechanisms and therapeutic interventions. Clin Sci (Lond) (2007) 1.79
Lack of the antioxidant enzyme glutathione peroxidase-1 accelerates atherosclerosis in diabetic apolipoprotein E-deficient mice. Circulation (2007) 1.74
Rat aortic MCP-1 and its receptor CCR2 increase with age and alter vascular smooth muscle cell function. Arterioscler Thromb Vasc Biol (2004) 1.68
Soluble RAGE in type 2 diabetes: association with oxidative stress. Free Radic Biol Med (2007) 1.67
RAGE modulates vascular inflammation and atherosclerosis in a murine model of type 2 diabetes. Atherosclerosis (2005) 1.67
Differential regulation of thioredoxin and NAD(P)H oxidase by angiotensin II in male and female mice. J Hypertens (2007) 1.65
Mobilization of CD34-positive bone marrow-derived cells after coronary stent implantation: impact on restenosis. Circulation (2007) 1.64
Diabetic microangiopathy in ischemic limb is a disease of disturbance of the platelet-derived growth factor-BB/protein kinase C axis but not of impaired expression of angiogenic factors. Circ Res (2005) 1.64
Nonenzymatic glycosylation in vitro and in bovine endothelial cells alters basic fibroblast growth factor activity. A model for intracellular glycosylation in diabetes. J Clin Invest (1994) 1.63
Endothelial progenitor thrombospondin-1 mediates diabetes-induced delay in reendothelialization following arterial injury. Circ Res (2006) 1.63
Recent advances in understanding endothelial dysfunction in atherosclerosis. Clin Med Res (2006) 1.62
Increased atherosclerosis in streptozotocin-induced diabetic mice. J Clin Invest (1996) 1.57
Vascular endothelial growth factor-A-induced chemotaxis of monocytes is attenuated in patients with diabetes mellitus: A potential predictor for the individual capacity to develop collaterals. Circulation (2000) 1.54
Allele-specific regulation of matrix metalloproteinase-12 gene activity is associated with coronary artery luminal dimensions in diabetic patients with manifest coronary artery disease. Circ Res (2000) 1.52
Diabetic retinopathy. Diabetes Care (2003) 1.52
Outcomes in patients with diabetes mellitus undergoing percutaneous coronary intervention in the current era: a report from the Prevention of REStenosis with Tranilast and its Outcomes (PRESTO) trial. Circulation (2004) 1.51
Hyperglycemia reduces survival and impairs function of circulating blood-derived progenitor cells. Arterioscler Thromb Vasc Biol (2005) 1.50
Growth factors in the treatment of diabetic foot ulcers. Br J Surg (2003) 1.49
Vascular structural and functional changes in type 2 diabetes mellitus: evidence for the roles of abnormal myogenic responsiveness and dyslipidemia. Circulation (2002) 1.47
Hsp90-Akt phosphorylates ASK1 and inhibits ASK1-mediated apoptosis. Oncogene (2005) 1.45
High glucose-induced apoptosis in human vascular endothelial cells is mediated through NF-kappaB and c-Jun NH2-terminal kinase pathway and prevented by PI3K/Akt/eNOS pathway. Cell Signal (2005) 1.43
High glucose-induced apoptosis in human endothelial cells is mediated by sequential activations of c-Jun NH(2)-terminal kinase and caspase-3. Circulation (2000) 1.43
Advanced glycation endproducts induce podocyte apoptosis by activation of the FOXO4 transcription factor. Kidney Int (2007) 1.42
Increased expression of basement membrane components in human endothelial cells cultured in high glucose. J Clin Invest (1988) 1.39
Impairment in ischemia-induced neovascularization in diabetes: bone marrow mononuclear cell dysfunction and therapeutic potential of placenta growth factor treatment. Am J Pathol (2004) 1.31
Human fetal aorta contains vascular progenitor cells capable of inducing vasculogenesis, angiogenesis, and myogenesis in vitro and in a murine model of peripheral ischemia. Am J Pathol (2007) 1.31
Therapeutic regulation of endothelial dysfunction in type 2 diabetes mellitus. Diab Vasc Dis Res (2007) 1.31
Nerve growth factor promotes reparative angiogenesis and inhibits endothelial apoptosis in cutaneous wounds of Type 1 diabetic mice. Diabetologia (2004) 1.27
Physiology and pathobiology of the pericyte-containing retinal microvasculature: new developments. Microcirculation (2007) 1.24
High glucose alters matrix metalloproteinase expression in two key vascular cells: potential impact on atherosclerosis in diabetes. Atherosclerosis (2003) 1.24
Receptor for advanced glycation end products is involved in impaired angiogenic response in diabetes. Diabetes (2006) 1.22
Human paraoxonase-1 overexpression inhibits atherosclerosis in a mouse model of metabolic syndrome. Arterioscler Thromb Vasc Biol (2006) 1.21
Chronic hyperglycemia attenuates coronary collateral development and impairs proliferative properties of myocardial interstitial fluid by production of angiostatin. Circulation (2004) 1.17
The burden of diabetes and its complications: trends and implications for intervention. Diabetes Res Clin Pract (2007) 1.16
Apoptosis signal-regulating kinase 1 mediates cellular senescence induced by high glucose in endothelial cells. Diabetes (2006) 1.16
High glucose increases the expression of Cbfa1 and BMP-2 and enhances the calcification of vascular smooth muscle cells. Nephrol Dial Transplant (2006) 1.15
Akt/protein kinase B and endothelial nitric oxide synthase mediate muscular neovascularization induced by tissue kallikrein gene transfer. Circulation (2004) 1.15
Regulation of endothelial derived nitric oxide in health and disease. Mem Inst Oswaldo Cruz (2005) 1.15
Effects of high glucose on vascular endothelial growth factor expression in vascular smooth muscle cells. Am J Physiol (1997) 1.14
Nerve growth factor supplementation reverses the impairment, induced by Type 1 diabetes, of hindlimb post-ischaemic recovery in mice. Diabetologia (2004) 1.12
p53 Mediates the accelerated onset of senescence of endothelial progenitor cells in diabetes. J Biol Chem (2005) 1.12
Glycated collagen I induces premature senescence-like phenotypic changes in endothelial cells. Circ Res (2002) 1.11
Hyperglycemia inhibits vascular smooth muscle cell apoptosis through a protein kinase C-dependent pathway. Circ Res (2000) 1.11
Simvastatin improves diabetes-induced coronary endothelial dysfunction. J Pharmacol Exp Ther (2006) 1.09
Mechanism of high glucose induced angiotensin II production in rat vascular smooth muscle cells. Circ Res (2007) 1.09
Adventitial progenitor cells contribute to arteriosclerosis. Trends Cardiovasc Med (2005) 1.08
Type-2 diabetic Lepr(db/db) mice show a defective microvascular phenotype under basal conditions and an impaired response to angiogenesis gene therapy in the setting of limb ischemia. Front Biosci (2007) 1.07
Evidence for a matrix metalloproteinase induction/activation system in arterial vasculature and decreased synthesis and activity in diabetes. Diabetes (2002) 1.05
Glomerular expression of the ATP-sensitive P2X receptor in diabetic and hypertensive rat models. Kidney Int (2004) 1.03
alpha-Lipoic acid prevents the increase in atherosclerosis induced by diabetes in apolipoprotein E-deficient mice fed high-fat/low-cholesterol diet. Diabetes (2006) 1.03
Prevention of diabetes-induced microangiopathy by human tissue kallikrein gene transfer. Circulation (2002) 1.03
Prophylactic gene therapy with human tissue kallikrein ameliorates limb ischemia recovery in type 1 diabetic mice. Diabetes (2004) 1.03
Leprdb diabetic mouse bone marrow cells inhibit skin wound vascularization but promote wound healing. Circ Res (2003) 1.03
Modification of vitronectin by advanced glycation alters functional properties in vitro and in the diabetic retina. Lab Invest (1996) 1.02
Hyperglycemia is a major determinant of albumin permeability in diabetic microcirculation: the role of mu-calpain. Diabetes (2007) 1.02
Opposite effects of high glucose on MMP-2 and TIMP-2 in human endothelial cells. J Cell Biochem (2007) 1.01
Human CD133+ progenitor cells promote the healing of diabetic ischemic ulcers by paracrine stimulation of angiogenesis and activation of Wnt signaling. Circ Res (2009) 3.25
Role of kinin B2 receptor signaling in the recruitment of circulating progenitor cells with neovascularization potential. Circ Res (2008) 2.12
Deregulation of microRNA-503 contributes to diabetes mellitus-induced impairment of endothelial function and reparative angiogenesis after limb ischemia. Circulation (2011) 1.99
Nerve growth factor promotes cardiac repair following myocardial infarction. Circ Res (2010) 1.94
Genetic deletion of the p66Shc adaptor protein protects from angiotensin II-induced myocardial damage. Hypertension (2005) 1.88
Nerve growth factor promotes angiogenesis and arteriogenesis in ischemic hindlimbs. Circulation (2002) 1.85
Transplantation of human pericyte progenitor cells improves the repair of infarcted heart through activation of an angiogenic program involving micro-RNA-132. Circ Res (2011) 1.78
Human adult vena saphena contains perivascular progenitor cells endowed with clonogenic and proangiogenic potential. Circulation (2010) 1.69
Critical role of tissue kallikrein in vessel formation and maturation: implications for therapeutic revascularization. Arterioscler Thromb Vasc Biol (2009) 1.67
Involvement of phosphoinositide 3-kinase gamma in angiogenesis and healing of experimental myocardial infarction in mice. Circ Res (2010) 1.63
Derivation of endothelial cells from human embryonic stem cells by directed differentiation: analysis of microRNA and angiogenesis in vitro and in vivo. Arterioscler Thromb Vasc Biol (2010) 1.63
Clinical-grade human neural stem cells promote reparative neovascularization in mouse models of hindlimb ischemia. Arterioscler Thromb Vasc Biol (2013) 1.52
Migratory activity of circulating progenitor cells and serum SDF-1α predict adverse events in patients with myocardial infarction. Cardiovasc Res (2013) 1.51
Cardiovascular actions of neurotrophins. Physiol Rev (2009) 1.45
Diabetes mellitus induces bone marrow microangiopathy. Arterioscler Thromb Vasc Biol (2009) 1.34
Human fetal aorta contains vascular progenitor cells capable of inducing vasculogenesis, angiogenesis, and myogenesis in vitro and in a murine model of peripheral ischemia. Am J Pathol (2007) 1.31
Role of microRNAs in diabetes and its cardiovascular complications. Cardiovasc Res (2011) 1.30
Neurotrophin p75 receptor (p75NTR) promotes endothelial cell apoptosis and inhibits angiogenesis: implications for diabetes-induced impaired neovascularization in ischemic limb muscles. Circ Res (2008) 1.29
Transplantation of low dose CD34+KDR+ cells promotes vascular and muscular regeneration in ischemic limbs. FASEB J (2004) 1.27
MicroRNA regulation in angiogenesis. Vascul Pharmacol (2011) 1.27
MicroRNA-15a and microRNA-16 impair human circulating proangiogenic cell functions and are increased in the proangiogenic cells and serum of patients with critical limb ischemia. Circ Res (2012) 1.19
Vitamin B1 analog benfotiamine prevents diabetes-induced diastolic dysfunction and heart failure through Akt/Pim-1-mediated survival pathway. Circ Heart Fail (2010) 1.19
Intravenous gene therapy with PIM-1 via a cardiotropic viral vector halts the progression of diabetic cardiomyopathy through promotion of prosurvival signaling. Circ Res (2011) 1.18
Role of microRNAs 99b, 181a, and 181b in the differentiation of human embryonic stem cells to vascular endothelial cells. Stem Cells (2012) 1.18
Phosphoinositide 3-kinase gamma gene knockout impairs postischemic neovascularization and endothelial progenitor cell functions. Arterioscler Thromb Vasc Biol (2007) 1.16
Mechanisms of disease: the tissue kallikrein-kinin system in hypertension and vascular remodeling. Nat Clin Pract Nephrol (2007) 1.16
Akt/protein kinase B and endothelial nitric oxide synthase mediate muscular neovascularization induced by tissue kallikrein gene transfer. Circulation (2004) 1.15
Perivascular delivery of encapsulated mesenchymal stem cells improves postischemic angiogenesis via paracrine activation of VEGF-A. Arterioscler Thromb Vasc Biol (2013) 1.11
Inhibition of delta-like-4-mediated signaling impairs reparative angiogenesis after ischemia. Circ Res (2010) 1.10
Global remodeling of the vascular stem cell niche in bone marrow of diabetic patients: implication of the microRNA-155/FOXO3a signaling pathway. Circ Res (2012) 1.09
Targeting kinin B(1) receptor for therapeutic neovascularization. Circulation (2002) 1.08
Benfotiamine improves functional recovery of the infarcted heart via activation of pro-survival G6PD/Akt signaling pathway and modulation of neurohormonal response. J Mol Cell Cardiol (2010) 1.08
Role for substance p-based nociceptive signaling in progenitor cell activation and angiogenesis during ischemia in mice and in human subjects. Circulation (2012) 1.07
Type-2 diabetic Lepr(db/db) mice show a defective microvascular phenotype under basal conditions and an impaired response to angiogenesis gene therapy in the setting of limb ischemia. Front Biosci (2007) 1.07
Protease-activated receptor-2 stimulates angiogenesis and accelerates hemodynamic recovery in a mouse model of hindlimb ischemia. Circ Res (2002) 1.05
Pluripotent stem cell differentiation into vascular cells: a novel technology with promises for vascular re(generation). Pharmacol Ther (2010) 1.05
Prevention of diabetes-induced microangiopathy by human tissue kallikrein gene transfer. Circulation (2002) 1.03
Prophylactic gene therapy with human tissue kallikrein ameliorates limb ischemia recovery in type 1 diabetic mice. Diabetes (2004) 1.03
MicroRNA-503 and the extended microRNA-16 family in angiogenesis. Trends Cardiovasc Med (2011) 1.02
Boosting the pentose phosphate pathway restores cardiac progenitor cell availability in diabetes. Cardiovasc Res (2012) 1.00
Nerve growth factor gene therapy using adeno-associated viral vectors prevents cardiomyopathy in type 1 diabetic mice. Diabetes (2012) 1.00
Regional and global protective effects of tissue kallikrein gene delivery to the peri-infarct myocardium. Regen Med (2006) 0.98
Paracrine control of vascularization and neurogenesis by neurotrophins. Br J Pharmacol (2003) 0.96
Targeting stem cell niches and trafficking for cardiovascular therapy. Pharmacol Ther (2010) 0.95
Concise review: MicroRNAs as modulators of stem cells and angiogenesis. Stem Cells (2014) 0.95
Tissue kallikrein is essential for invasive capacity of circulating proangiogenic cells. Circ Res (2010) 0.94
Local inhibition of microRNA-24 improves reparative angiogenesis and left ventricle remodeling and function in mice with myocardial infarction. Mol Ther (2013) 0.94
Rapid onset of cardiomyopathy in STZ-induced female diabetic mice involves the downregulation of pro-survival Pim-1. Cardiovasc Diabetol (2014) 0.92
Possible novel targets for therapeutic angiogenesis. Curr Opin Pharmacol (2008) 0.91
Cardiac hypertrophy and microvascular deficit in kinin B2 receptor knockout mice. Hypertension (2003) 0.91
Angiotensin AT(1) receptor signalling modulates reparative angiogenesis induced by limb ischaemia. Br J Pharmacol (2002) 0.90
Diabetes causes bone marrow endothelial barrier dysfunction by activation of the RhoA-Rho-associated kinase signaling pathway. Arterioscler Thromb Vasc Biol (2013) 0.88
Neurotrophin-3 is a novel angiogenic factor capable of therapeutic neovascularization in a mouse model of limb ischemia. Arterioscler Thromb Vasc Biol (2010) 0.88
Vascular differentiation from embryonic stem cells: novel technologies and therapeutic promises. Vascul Pharmacol (2012) 0.88
Reversal of angiogenic growth factor upregulation by revascularization of lower limb ischemia. Circulation (2002) 0.88
Human adult skeletal muscle stem cells differentiate into cardiomyocyte phenotype in vitro. Exp Cell Res (2007) 0.88
Ex vivo molecular rejuvenation improves the therapeutic activity of senescent human cardiac stem cells in a mouse model of myocardial infarction. Stem Cells (2014) 0.87
Omentum-derived stromal cells improve myocardial regeneration in pig post-infarcted heart through a potent paracrine mechanism. Exp Cell Res (2010) 0.87
Pre-emptive hypoxia-regulated HO-1 gene therapy improves post-ischaemic limb perfusion and tissue regeneration in mice. Cardiovasc Res (2012) 0.87
What's new in regenerative medicine: split up of the mesenchymal stem cell family promises new hope for cardiovascular repair. J Cardiovasc Transl Res (2012) 0.87
Apricot melanoidins prevent oxidative endothelial cell death by counteracting mitochondrial oxidation and membrane depolarization. PLoS One (2012) 0.86
Therapeutic angiogenesis: translating experimental concepts to medically relevant goals. Vascul Pharmacol (2006) 0.85
Systemic VEGF inhibition accelerates experimental atherosclerosis and disrupts endothelial homeostasis--implications for cardiovascular safety. Int J Cardiol (2013) 0.85
Notch signalling in ischaemia-induced angiogenesis. Biochem Soc Trans (2009) 0.85
Circulating tissue kallikrein levels correlate with severity of carotid atherosclerosis. Arterioscler Thromb Vasc Biol (2004) 0.84